Neurology

Discussion in 'Valeant Pharmaceuticals' started by anonymous, Sep 22, 2017 at 7:24 PM.

Tags: Add Tags
  1. anonymous

    anonymous Guest

    Didn't this division of contract reps get created just a few months ago? Apparently, just because some telemarketing efforts to call office staff and not doctors led Pappa to believe there was a great opportunity to sell an ancient but effective brand generic migraine drug after some of his head nodding management team over promised on some unrealistic sales goals. Once securing an underpaid, 60k or less, contracted salesforce in place with very little training and resources, Valeant management in all its delusions of grandeur believed they could get double digit sales growth in less than 105 days. Really?

    On top of all that, this rag tag management team of first time wet behind the ears go getters had the gall to berate the salesforce on a teleconference that they weren't growing fast enough when they barely know their customers yet. Are you kidding me? This isn't a cure for migraines. It's an old drug most doctors forgot about that provides some relief. It's going to take more than 4 months to move the product and badgering customers on a weekly basis by aggressively challenging them to use the product is not conducive for sales reps to maintain access after only calling on them in less than four months.

    Can you please come back to reality? Neurology didn't put the company billions of dollars in debt. Bad management decisions did. Talk to the Neurology team 8 months from now. If they are still underperforming then you have a leg to stand on. They haven't worked a full quarter yet for peanuts and you are whining. Get real.
     

  2. anonymous

    anonymous Guest

    I heard about that Friday morning national teleconference. What an insult! So glad I passed on taking that Alamo gig with Valeant Neurology. Obviously, this amateur management team has no clue nor do they care that it will take some time to get the docs to write Migranal.
     
  3. anonymous

    anonymous Guest

    Valeant is still in dreamland, thinking that all is well and that they are holier than thou! Valeant is full of fraudsters and scamsters and are in perpetual denial. Fools!!!!
     
  4. anonymous

    anonymous Guest

    We're doing fine. All companies have issues, we just need to grind through it. All those who caused damage to us are long gone. Have some faith.
     
  5. anonymous

    anonymous Guest

    I will have some faith when the Valeant management team learns not to rip it's brand new Neurology team for poor performance before they study sales trends. Historically, summer months are slower for use of migraine meds. Change of seasons like Spring to Summer and Summer to Winter are when migraine medication use jumps up dramatically. Also, fixing the issue of providers and their scripts getting left out or mysteriously being removed from targeting lists would be nice before accusing the division of poor sales performances. What's up with that nonsense?
     
  6. anonymous

    anonymous Guest

    Could just be your products suck.
     
  7. anonymous

    anonymous Guest

    You may have a valid point. The sales rep pay sucks too with a mostly novice and naive management team micromanaging them.
     
  8. anonymous

    anonymous Guest

    POA meeting was a joke. I doubt the division will be around in 6 months.
     
  9. anonymous

    anonymous Guest

    The management team knows nothing about the migraine market, they are frustrated because many of the reps have figured out they are disorganized and they want the reps to give them a chance to get it together. However, if the sales numbers of the reps aren't good whether reps have only been here a quarter or two, they are ready to put them on improvement plans or fire them if they don't agree with management's methods. Can you say hypocritical?
     
  10. anonymous

    anonymous Guest

    The leaders of this division are hypocrites because they want reps to give them a chance to get better but they are quick to demoralize reps if their numbers aren't good even though most reps have been here less than 6 months. Really?
     
  11. anonymous

    anonymous Guest

    is this division around
     
  12. anonymous

    anonymous Guest

    Yes, the McKinley division is still here.
     
  13. anonymous

    anonymous Guest

    Funny how upper management is quick to put pressure on reps they feel are underperforming but they have no answers for the discrepancy in the M numbers that have had to be adjusted on a few occasions. Can anyone explain the numbers in Dallas or San Antonio? Curious.
     
  14. anonymous

    anonymous Guest

    Upper management is putting pressure on all reps in all divisions. This is the most toxic work environment I have ever been. Everyone I know is looking for another job, just that there's not many out there in pharma sales.
     
  15. anonymous

    anonymous Guest

    I am appalled at excessive pricing of Mysoline, which has been around for at least 30 years. Why?
     
  16. anonymous

    anonymous Guest

    It is part of their business model. They have no interest in creating new medicines to help people. Think of the company as a get rich quick fund for its greedy baby boomer investors.
     
  17. anonymous

    anonymous Guest

    Is it normal for a doc to write 132 Rxs in 1 week and management not question it? Only in Valeant. Oh wait let me use their alias now that they are hiding from their questionable past, Bausch Healthcare Scam Cos., Inc.
     
  18. anonymous

    anonymous Guest

    Something fishy may be going w/ territories in the division. Some of the weekly script totals are off the charts. Are their certain pharmacies being "extra friendly" to certain practices?
     
  19. anonymous

    anonymous Guest

    Sooooo, management is just going to pretend this is normal and continuing to suggest a certain channel of distribution. Interesting.
     
  20. anonymous

    anonymous Guest

    Fishy? This ship called Migranal has been sinking for a while and the boat is getting light because the smart folks are leaving. How can this management team think Migranal can grow when there are now 2 CGRP drugs in the market and 1 more CGRP coming out soon that directly competes against Migranal?